technetium tc 99m sestamibi has been researched along with Diabetic Nephropathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fuster, D; Laterza, C; Magriñá, J; Martín, F; Mateos, JJ; Muxí, A; Pascual, J; Ricart, MJ; Setoain, FJ; Vidal-Sicart, S | 1 |
| Bueno, FS; Claver, MA; Fernández, JA; Gimeno, L; Llorente, S; Luján, JA; Munítiz, V; Parrilla, P; Ramírez, P; Robles, R; Rodríguez, JM | 1 |
2 other study(ies) available for technetium tc 99m sestamibi and Diabetic Nephropathies
| Article | Year |
|---|---|
Noninvasive assessment of cardiac risk in type I diabetic patients being evaluated for combined pancreas-kidney transplantation using dipyridamole-MIBI perfusion tomographic scintigraphy.
Topics: Adult; Contraindications; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipyridamole; Exercise Test; Female; Heart; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Myocardial Ischemia; Pancreas Transplantation; Postoperative Complications; Radiopharmaceuticals; Risk Assessment; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2000 |
Clinical noninvasive evaluation of simultaneous pancreas-kidney transplants with the combined use of gammagraphy, Doppler ultrasound, and serum markers.
Topics: Amylases; Biomarkers; Biopsy; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Graft Survival; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lipase; Pancreas Transplantation; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Treatment Outcome; Ultrasonography, Doppler | 2002 |